Investigating the effects of hormone therapy on HIV prevention in transgender individuals
CHIPP-PrEP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics for HIV Prevention in Cisgender and Transgender Persons
This study is looking at how estrogen hormone therapy affects the way the HIV prevention pill cabotegravir works in transgender women and gender diverse people, so we can make sure they can safely use this medication while on hormone therapy.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11002040 on NIH RePORTER |
What this research studies
This research focuses on understanding how estrogen-based gender affirming hormone therapy (GAHT) affects the pharmacokinetics and pharmacodynamics of cabotegravir, a medication used for HIV prevention, in transgender women and gender diverse individuals assigned male at birth. The study aims to improve healthcare for these populations by examining the interaction between GAHT and long-acting cabotegravir for pre-exposure prophylaxis (PrEP). By characterizing these relationships, the research seeks to ensure that transgender individuals can safely and effectively use PrEP while undergoing hormone therapy. Participants will be monitored for drug concentrations and other pharmacological parameters to assess the effectiveness of this preventive treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research include transgender women and gender diverse persons assigned male at birth who are currently receiving or considering estrogen-based hormone therapy.
Not a fit: Patients who are not transgender or gender diverse and do not use hormone therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance HIV prevention strategies for transgender individuals, leading to better health outcomes and quality of life.
How similar studies have performed: Previous studies have shown promising results in HIV prevention using cabotegravir, particularly in populations similar to those targeted in this research, indicating a potential for success.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Marzinke, Mark a — Johns Hopkins University
- Study coordinator: Marzinke, Mark a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.